Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > ACADEMIA
ACADEMIA
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
- Arzerra, Japan’s 1st Antibody for CLL, Will Expand Treatment Options: Dr Ogawa of Tokai Univ.
July 11, 2013
- Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
July 11, 2013
- Orencia Particularly Suitable for Elderly RA Patients: Prof. Takeuchi of Keio University
July 8, 2013
- “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
- NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
- JSOG Sets Up Investigative Panel on HPV Vaccines to Examine Safety
June 26, 2013
- Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA
June 25, 2013
- SCJ Statement Calls for Close Consultation with Experts in Planning Japanese Version of NIH
June 25, 2013
- Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
- More Treatment Options for FD Patients with Acofide Launch: Prof. Kinoshita of Shimane University
June 11, 2013
- Clinical Pharmacology Network to Go Into Operation with 8 Institutions
June 6, 2013
- Japan College of Rheumatology Issues Guidelines on Xeljanz Use
June 6, 2013
- Cetuximab Add-on Therapy Fails to Improve PFS in Operable Colorectal Liver Metastasis Patients: ASCO
June 4, 2013
- Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz
May 31, 2013
- Researcher Wearing Two Hats Should Disclose Affiliation with Greater Interests in Trials: Japan Hypertension Society
May 30, 2013
- JAMS Recognizes Violation of COI Reporting Rules over Diovan Papers
May 28, 2013
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…